Navana Pharmaceuticals Income Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Revenue	7,404	6,898	5,706	4,759	3,607	3,149
Revenue Growth (YoY)	23.37%	20.89%	19.91%	31.95%	14.53%	-
Cost of Revenue	4,032	3,770	3,110	2,599	1,993	1,740
Gross Profit	3,372	3,128	2,596	2,160	1,614	1,409
Selling, General & Admin	2,236	2,136	1,841	1,591	1,265	1,135
Operating Expenses	2,236	2,136	1,841	1,591	1,265	1,135
Operating Income	1,136	991.84	755.72	569.6	348.59	274.18
Interest Expense	-582.08	-463.57	-234.89	-200.42	-75.18	-91.59
Interest & Investment Income	1.52	1.47	5.84	5.58	0.03	0.04
Currency Exchange Gain (Loss)	-27.97	-25.18	-33.38	-93.98	-2.52	-5.11
Other Non Operating Income (Expenses)	10.57	11.39	-1.91	27.64	30.47	22.09
EBT Excluding Unusual Items	538.16	515.95	491.38	308.42	301.39	199.6
Gain (Loss) on Sale of Investments	-11.91	-0.88	-42.3	82.9	-	19.68
Gain (Loss) on Sale of Assets	1.18	1.18	-	0.47	1.02	-
Pretax Income	527.42	516.25	449.08	391.79	302.41	219.28
Income Tax Expense	101.53	111.62	92.14	117.78	100.12	81.88
Net Income	425.89	404.63	356.94	274	202.29	137.4
Net Income to Common	420.22	404.63	356.94	274	202.29	137.4
Net Income Growth	7.33%	13.36%	30.27%	35.45%	47.23%	-
Shares Outstanding (Basic)	108	107	99	80	80	80
Shares Outstanding (Diluted)	108	107	99	80	80	80
Shares Change (YoY)	1.72%	8.05%	23.91%	-	-	-
EPS (Basic)	3.90	3.77	3.59	3.42	2.52	1.71
EPS (Diluted)	3.90	3.77	3.59	3.42	2.52	1.71
EPS Growth	2.65%	4.92%	5.13%	35.45%	47.23%	-
Free Cash Flow	-601.78	-625.1	-1,404	-1,160	-399	181.8
Free Cash Flow Per Share	-5.59	-5.82	-14.13	-14.45	-4.97	2.27
Dividend Per Share	1.400	1.400	1.300	1.100	-	-
Dividend Growth	7.69%	7.69%	18.18%	-	-	-
Gross Margin	45.54%	45.34%	45.50%	45.39%	44.74%	44.73%
Operating Margin	15.34%	14.38%	13.24%	11.97%	9.67%	8.71%
Profit Margin	5.68%	5.87%	6.26%	5.76%	5.61%	4.36%
Free Cash Flow Margin	-8.13%	-9.06%	-24.61%	-24.37%	-11.06%	5.77%
EBITDA	1,313	1,163	966.13	675.37	397.71	314.49
EBITDA Margin	17.73%	16.86%	16.93%	14.19%	11.03%	9.99%
D&A For EBITDA	176.71	171.25	210.41	105.77	49.12	40.31
EBIT	1,136	991.84	755.72	569.6	348.59	274.18
EBIT Margin	15.34%	14.38%	13.24%	11.97%	9.67%	8.71%
Effective Tax Rate	19.25%	21.62%	20.52%	30.06%	33.11%	37.34%
Advertising Expenses	-	38.4	33.13	80.86	19.55	16.63

Source: S&P Capital IQ. Standard template. Financial Sources.